Bioalliance PharmaAct Nom. Cat-P News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.09.24	Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics Company (Businesswire)
07.04.22	Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer (Businesswire)
13.04.21	Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised (Businesswire)
10.03.21	Onxeo Launches a Rights Issue to Accelerate Its R&D Programs (Businesswire)
09.06.20	Onxeo Announces a Capital Increase of €7.3 Million by Private Placement to Invus and Financière de la Montagne, the Company's Historical Shareholder (Businesswire)
13.11.19	Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology (Businesswire)
04.11.19	Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment (Businesswire)
03.01.19	Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor (Businesswire)
18.12.18	Onxeo Receives EPO Intent-to-Grant Notice for New Patent Protecting AsiDNA™ in Combination with Any PARP Inhibitor (Businesswire)
05.11.18	Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNATM, a First-In-Class DNA Damage Response Inhibitor (Businesswire)
18.10.18	Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019 (Businesswire)
27.07.18	Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook (Businesswire)
12.07.18	New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors (Businesswire)
15.06.18	Onxeo Implements an Equity Line Financing Including an Incentive Program with Nice & Green SA (Businesswire)
15.03.18	Onxeo to Present Results of Two Studies Highlighting Potential of AsiDNA™ as Anti-Cancer Treatment at 2018 AACR Annual Meeting (Businesswire)
25.01.18	Onxeo Receives EPO Intent-to-Grant Notice for Key AsiDNA™ Patent, Extending IP Protection in Europe Until 2031 (Businesswire)
23.01.18	Onxeo Provides Update on Litigation with SpeBio/SpePharm (Businesswire)
23.01.18	Onxeo Announces Its Financial Agenda For 2018 (Businesswire)
08.01.18	Summary of Onxeo’s Liquidity Contract With CM-CIC SECURITIES (Businesswire)
03.01.18	Onxeo to Attend Key Investor and Partnering Conferences in H1 2018 (Businesswire)
28.11.17	Onxeo Establishes Scientific Advisory Board with International Experts in DNA-Targeting (Businesswire)
26.10.17	Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information (Businesswire)
17.10.17	Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm (Businesswire)
02.10.17	Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides (Businesswire)
28.09.17	Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat. (Businesswire)
18.09.17	Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag® (Businesswire)
13.09.17	Onxeo Grants Exclusive Worldwide License of Validive® Developed for the Treatment of Oral Severe Mucositis to Monopar Therapeutics (Businesswire)
11.09.17	Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in Advanced Hepatocellular Carcinoma (Businesswire)
31.07.17	Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma (Businesswire)
28.07.17	Onxeo Reports First-Half 2017 Results and Business Update (Businesswire)
06.07.17	Summary of Onxeo’s Liquidity Contract With CM-CIC SECURITIES (Businesswire)
01.03.17	Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development (Businesswire)
09.01.17	Summary of Onxeo’s Liquidity Contract With CIC (Businesswire)
07.12.16	Onxeo Announces Its Financial Calendar for 2017 (Businesswire)
29.11.16	Onxeo Strengthens AsiDNATM Patent Protection in Europe (Businesswire)
28.11.16	Onxeo to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference (Businesswire)
21.11.16	Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC (Businesswire)
04.11.16	Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer (Businesswire)
27.10.16	Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors (Businesswire)
25.10.16	Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update (Businesswire)
10.10.16	Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco (Businesswire)
29.09.16	Onxeo Launches Capital Increase (Businesswire)
12.09.16	Onxeo Announces First Outcomes of Livatag® Preclinical Plan (Businesswire)
07.09.16	Onxeo to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York (Businesswire)
28.07.16	Onxeo Reports First-Half 2016 Business Update and Consolidated Financials (Businesswire)
27.07.16	Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America (Businesswire)
07.07.16	Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives (Businesswire)
04.07.16	Onxeo Receives USPTO Notice of Allowance for Key AsiDNATM Patent, Extending IP Protection in the U.S. until 2031 (Businesswire)
27.06.16	Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA (Businesswire)
02.06.16	Onxeo Announces Development of Beleodaq® Oral Formulation Opening New Opportunities for Its HDAC Inhibitor (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Bioalliance PharmaAct Nom. Cat-P

Aktien Top/Flop

Meistgelesene Nachrichten